Cargando…

Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?

Nonalcoholic steatohepatitis (NASH) is a progressed stage of non-alcoholic fatty liver disease, and available therapeutic strategies for NASH are limited. Vitamin D receptor (VDR) is proposed as a druggable target for NASH due to the discovery of vitamin D deficiency in NASH patients. To date, vitam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Ying, Shu, Xiang-Bing, Yao, Zemin, Ji, Guang, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579753/ https://www.ncbi.nlm.nih.gov/pubmed/33132636 http://dx.doi.org/10.3748/wjg.v26.i38.5812

Ejemplares similares

Mechanisms of ductular reaction in non-alcoholic steatohepatitis
por: Chen, Yue, et al.
Publicado: (2022)

Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis
por: Suri, Jaspreet, et al.
Publicado: (2022)

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
por: Tovo, Cristiane Valle, et al.
Publicado: (2023)

Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
por: Kram, Michael
Publicado: (2023)

Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
por: Chackelevicius, Carla Melisa, et al.
Publicado: (2016)

Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
por: Ocker, Matthias
Publicado: (2020)

Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do
por: Sanchez-Torrijos, Yolanda, et al.
Publicado: (2017)

Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis
por: Seen, Tasur Kumar, et al.
Publicado: (2021)

SNAIL vs vitamin D receptor expression in colon cancer: therapeutics implications
por: Larriba, M J, et al.
Publicado: (2005)

Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome
por: Sheng, Wei, et al.
Publicado: (2022)

Vitamin D and spine surgery
por: Mabey, Thomas, et al.
Publicado: (2016)

Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma
por: Takakura, Kazuki, et al.
Publicado: (2018)

Role of in vitamin D in irritable bowel syndrome
por: Yu, Xiao-Lan, et al.
Publicado: (2023)

New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders
por: Jamshed, Fatima, et al.
Publicado: (2023)

Natural products that target macrophages in treating non-alcoholic steatohepatitis
por: Li, Chun-Lin, et al.
Publicado: (2020)

Vitamin D in esophageal cancer: Is there a role for chemoprevention?
por: Rouphael, Carol, et al.
Publicado: (2018)

Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis
por: Pejnovic, Nada, et al.
Publicado: (2016)

Vitamin D and calcium signaling in epidermal stem cells and their regeneration
por: Oda, Yuko, et al.
Publicado: (2020)

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020)

A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
por: Skat‐Rørdam, Josephine, et al.
Publicado: (2019)

Liver regeneration as treatment target for severe alcoholic hepatitis
por: Virovic-Jukic, Lucija, et al.
Publicado: (2022)

Role of macrophage scavenger receptor MSR1 in the progression of non-alcoholic steatohepatitis
por: Sheng, Wei, et al.
Publicado: (2022)

Vitamin D in Renal Transplantation – from Biological Mechanisms to Clinical Benefits
por: McGregor, R, et al.
Publicado: (2014)

Association of vitamin D and magnesium with insulin sensitivity and their influence on glycemic control
por: Wan Nik, Wan Nor Fazila Hafizan, et al.
Publicado: (2023)

Latest therapeutic target for gastric cancer: Anthrax toxin receptor 1
por: Sun, Ke-Ran, et al.
Publicado: (2021)

Beneficial Effects of Vitamin D Treatment in an Obese Mouse Model of Non-Alcoholic Steatohepatitis
por: Jahn, Daniel, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Research progress on the mitochondrial mechanism of age-related non-alcoholic fatty liver
por: Wang, Dan, et al.
Publicado: (2023)

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation
por: Shu, Xiangbing, et al.
Publicado: (2021)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Eph receptors as therapeutic targets in glioblastoma
por: Day, B W, et al.
Publicado: (2014)

The Role of Vitamin D in Inflammatory Bowel Disease – Assessing Therapeutic and Preventive Potential of Supplementation and Food Fortification
por: Leskovar, Dunja, et al.
Publicado: (2018)

Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence
por: Jeyakumar, Shanmugam Murugaiha, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease and cardiovascular risk
por: Patil, Rashmee, et al.
Publicado: (2017)

Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
por: Wong, Carrie R, et al.
Publicado: (2016)

Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Said, Adnan, et al.
Publicado: (2017)

RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets
por: Chen, Shao-Long, et al.
Publicado: (2021)

Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity
por: Neuzil, J
Publicado: (2003)

Racial differences in prevalence and severity of non-alcoholic fatty liver disease
por: Bonacini, Maurizio, et al.
Publicado: (2021)

Therapies for non-alcoholic fatty liver disease: A 2022 update
por: Shen, Katie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t7lnhq37ot19o4idpvp8kf4aga